Lifespan Analysis of 212 Transplanted Kidney Grafts: Effects of Use of Humanized Anti–IL-2R Monoclonal Antibody in Graft Survival at 1, 3, and 5 Years for 108 Recipients

References 

1. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs. 2005;9:39
2. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2004;1:CD003897
3. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Denmark Pediatr Transplant. 2000;9:373
4. Morris JA, Hanson JE, Steffen BJ, et al. Daclizumab id associated with decreased rejection and improved patient survival in renal transplant recipients. Denmark Clin Transplant. 2005;19:340
5. Stratta RJ, Alloway RR, Lo A, et al. PIVOT Study Group: One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. Transplant Proc. 2004;36:1080
   • Abstract
   • Full Text
   • Full-Text PDF (49 KB)
   • CrossRef
6. Ingle GR, Moudgil A, Vo A, et al. Cyclosporine-sparing effects of daclizumab in renal allograft recipients. Am J Health Syst Pharm. 2005;62:391
   • MEDLINE